Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "cardiovascular"

315 News Found

Remedium Lifecare charts 4X growth strategy
News | August 26, 2025

Remedium Lifecare charts 4X growth strategy

The first pillar is advanced manufacturing, focused on upgrading existing CDMO


Terumo India launches Terufusion advanced infusion systems in India
News | August 26, 2025

Terumo India launches Terufusion advanced infusion systems in India

Terufusion Advanced Infusion Systems combine a smart syringe pump, smart infusion pump, and pump monitoring system software for precise and efficient drug administration


J&J  to invest $2 billion at CDMO Fujifilm’s new hub
News | August 25, 2025

J&J to invest $2 billion at CDMO Fujifilm’s new hub

Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.


Novo Nordisk's Wegovy approved in the US for the treatment of MASH
News | August 19, 2025

Novo Nordisk's Wegovy approved in the US for the treatment of MASH

The accelerated approval is supported by results from part 1 of the ESSENCE trial


BioAge Labs doses first patient in BGE-102 phase 1 trial
Biotech | August 19, 2025

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants


Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity
Diagnostic Center | August 02, 2025

Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity

The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity


FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%
Drug Approval | July 15, 2025

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,


AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Diagnostic Center | July 14, 2025

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo


Evonik opens new medical device center in Shanghai
News | July 12, 2025

Evonik opens new medical device center in Shanghai

The company’s largest center for medical device applications, serving the entire Asian market